RU2006136786A - Иммуногенные гибридные полипептиды против ожирения и вакцинная композиция против ожирения, включающая эти полипептиды - Google Patents

Иммуногенные гибридные полипептиды против ожирения и вакцинная композиция против ожирения, включающая эти полипептиды Download PDF

Info

Publication number
RU2006136786A
RU2006136786A RU2006136786/13A RU2006136786A RU2006136786A RU 2006136786 A RU2006136786 A RU 2006136786A RU 2006136786/13 A RU2006136786/13 A RU 2006136786/13A RU 2006136786 A RU2006136786 A RU 2006136786A RU 2006136786 A RU2006136786 A RU 2006136786A
Authority
RU
Russia
Prior art keywords
polypeptide according
helper
seq
amino acid
acid sequence
Prior art date
Application number
RU2006136786/13A
Other languages
English (en)
Other versions
RU2341534C2 (ru
Inventor
Хуо-Дзун КИМ (KR)
Хуо-Дзун КИМ
Original Assignee
СДж БИОМЕД ИНК. (KR)
СДж БИОМЕД ИНК.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by СДж БИОМЕД ИНК. (KR), СДж БИОМЕД ИНК. filed Critical СДж БИОМЕД ИНК. (KR)
Publication of RU2006136786A publication Critical patent/RU2006136786A/ru
Application granted granted Critical
Publication of RU2341534C2 publication Critical patent/RU2341534C2/ru

Links

Classifications

    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F25—REFRIGERATION OR COOLING; COMBINED HEATING AND REFRIGERATION SYSTEMS; HEAT PUMP SYSTEMS; MANUFACTURE OR STORAGE OF ICE; LIQUEFACTION SOLIDIFICATION OF GASES
    • F25D—REFRIGERATORS; COLD ROOMS; ICE-BOXES; COOLING OR FREEZING APPARATUS NOT OTHERWISE PROVIDED FOR
    • F25D17/00—Arrangements for circulating cooling fluids; Arrangements for circulating gas, e.g. air, within refrigerated spaces
    • F25D17/04—Arrangements for circulating cooling fluids; Arrangements for circulating gas, e.g. air, within refrigerated spaces for circulating air, e.g. by convection
    • F25D17/06—Arrangements for circulating cooling fluids; Arrangements for circulating gas, e.g. air, within refrigerated spaces for circulating air, e.g. by convection by forced circulation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L9/00—Disinfection, sterilisation or deodorisation of air
    • A61L9/01—Deodorant compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L9/00—Disinfection, sterilisation or deodorisation of air
    • A61L9/16—Disinfection, sterilisation or deodorisation of air using physical phenomena
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2209/00—Aspects relating to disinfection, sterilisation or deodorisation of air
    • A61L2209/10—Apparatus features
    • A61L2209/12—Lighting means
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F25—REFRIGERATION OR COOLING; COMBINED HEATING AND REFRIGERATION SYSTEMS; HEAT PUMP SYSTEMS; MANUFACTURE OR STORAGE OF ICE; LIQUEFACTION SOLIDIFICATION OF GASES
    • F25D—REFRIGERATORS; COLD ROOMS; ICE-BOXES; COOLING OR FREEZING APPARATUS NOT OTHERWISE PROVIDED FOR
    • F25D2317/00—Details or arrangements for circulating cooling fluids; Details or arrangements for circulating gas, e.g. air, within refrigerated spaces, not provided for in other groups of this subclass
    • F25D2317/04—Treating air flowing to refrigeration compartments
    • F25D2317/041—Treating air flowing to refrigeration compartments by purification
    • F25D2317/0415—Treating air flowing to refrigeration compartments by purification by deodorizing
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F25—REFRIGERATION OR COOLING; COMBINED HEATING AND REFRIGERATION SYSTEMS; HEAT PUMP SYSTEMS; MANUFACTURE OR STORAGE OF ICE; LIQUEFACTION SOLIDIFICATION OF GASES
    • F25D—REFRIGERATORS; COLD ROOMS; ICE-BOXES; COOLING OR FREEZING APPARATUS NOT OTHERWISE PROVIDED FOR
    • F25D2317/00—Details or arrangements for circulating cooling fluids; Details or arrangements for circulating gas, e.g. air, within refrigerated spaces, not provided for in other groups of this subclass
    • F25D2317/04—Treating air flowing to refrigeration compartments
    • F25D2317/041—Treating air flowing to refrigeration compartments by purification
    • F25D2317/0417—Treating air flowing to refrigeration compartments by purification using an UV-lamp
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F25—REFRIGERATION OR COOLING; COMBINED HEATING AND REFRIGERATION SYSTEMS; HEAT PUMP SYSTEMS; MANUFACTURE OR STORAGE OF ICE; LIQUEFACTION SOLIDIFICATION OF GASES
    • F25D—REFRIGERATORS; COLD ROOMS; ICE-BOXES; COOLING OR FREEZING APPARATUS NOT OTHERWISE PROVIDED FOR
    • F25D2317/00—Details or arrangements for circulating cooling fluids; Details or arrangements for circulating gas, e.g. air, within refrigerated spaces, not provided for in other groups of this subclass
    • F25D2317/06—Details or arrangements for circulating cooling fluids; Details or arrangements for circulating gas, e.g. air, within refrigerated spaces, not provided for in other groups of this subclass with forced air circulation
    • F25D2317/068—Details or arrangements for circulating cooling fluids; Details or arrangements for circulating gas, e.g. air, within refrigerated spaces, not provided for in other groups of this subclass with forced air circulation characterised by the fans
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Thermal Sciences (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Mechanical Engineering (AREA)
  • Physics & Mathematics (AREA)
  • Combustion & Propulsion (AREA)
  • Peptides Or Proteins (AREA)

Claims (15)

1. Иммуногенный гибридный полипептид, в котором С-концевая часть пептида, включающая аминокислотную последовательность, выбранную из SEQ ID Nos. 1, 2 и 3, слита с N-концевой частью Т-хелперного эпитопа.
2. Полипептид по п.1, в котором пептид получают соединением от двух до восьми копий аминокислотной последовательности, выбранной из SEQ ID Nos. 1, 2 и 3.
3. Полипептид по п.2, в котором пептид получают соединением четырех копий аминокислотной последовательности, выбранной из SEQ ID Nos. 1, 2 и 3.
4. Полипептид по п.3, в котором пептид получают соединением четырех копий аминокислотной последовательности SEQ ID Nos. 1.
5. Полипептид по п.4, в котором пептид является полипептидом, имеющим аминокислотную последовательность SEQ ID Nos. 5.
6. Полипептид по п.1, в котором Т-хелперный эпитоп выбирают из группы, состоящей из Т-хелперных эпитопов поверхностного антигена гепатита В, Т-хелперных эпитопов главного белка внешней мембраны Chlamydia trachomitis, Т-хелперных эпитопов кольцевого спорозоита Plasmodium falciparum Т-хелперных эпитопов Escherichia coli TraT, Т-хелперных эпитопов столбнячного токсоида, Т-хелперных эпитопов дифтерийного токсоида, Т-хелперных эпитопов триозофосфатизомеразы Schistosoma mansoni, Т-хелперных эпитопов F-белка вируса кори и Т-хелперных эпитопов вируса бешенства.
7. Полипептид по п.6, в котором Т-хелперный эпитоп является Т-хелперным эпитопом поверхностного антигена гепатита В.
8. Полипептид по п.7, в котором Т-хелперный эпитоп является Т-хелперным эпитопом preS2 поверхностного антигена гепатита В.
9. Полипептид по п.8, в котором Т-хелперный эпитоп имеет аминокислотную последовательность SEQ ID No. 7.
10. Полипептид по п.1, который имеет аминокислотную последовательность SEQ ID No. 9.
11. Вакцина для предупреждения или лечения ожирения, включающая полипептид по любому из пп.1-10.
12. Рекомбинантный вектор, включающий ген, кодирующий полипептид по любому из пп.1-10.
13. Рекомбинантный вектор по п.12, который является pBl4Т (КССМ-10562).
14. Клетка-хозяин, трансформированная рекомбинантным вектором по п.12.
15. Способ получения полипептида по п.1 с помощью культивирования клетки-хозяина, трансформированной рекомбинантным вектором по п.12.
RU2006136786/13A 2004-03-18 2005-03-18 Иммуногенный гибридный полипептид против ожирения и вакцинная композиция на его основе RU2341534C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020040018551A KR100639397B1 (ko) 2004-03-18 2004-03-18 항비만용 면역원성 하이브리드 폴리펩타이드 및 이를포함하는 항비만 백신 조성물
KR10-2004-0018551 2004-03-18

Publications (2)

Publication Number Publication Date
RU2006136786A true RU2006136786A (ru) 2008-04-27
RU2341534C2 RU2341534C2 (ru) 2008-12-20

Family

ID=35064517

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2006136786/13A RU2341534C2 (ru) 2004-03-18 2005-03-18 Иммуногенный гибридный полипептид против ожирения и вакцинная композиция на его основе

Country Status (12)

Country Link
US (1) US7829667B2 (ru)
EP (1) EP1756143B1 (ru)
JP (1) JP4554672B2 (ru)
KR (1) KR100639397B1 (ru)
CN (1) CN1956995B (ru)
AT (1) ATE531730T1 (ru)
AU (1) AU2005222019B2 (ru)
BR (1) BRPI0508916A (ru)
CA (1) CA2560539C (ru)
MX (1) MXPA06010635A (ru)
RU (1) RU2341534C2 (ru)
WO (1) WO2005087800A1 (ru)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2076544A4 (en) * 2006-09-25 2009-11-11 Sj Biomed Inc ANTI-OBESITY IMMONOGENIC HYBRID POLYPEPTIDES AND ANTI-OBESITY VACCINE COMPOSITION COMPRISING THE SAME
US10858422B2 (en) 2016-05-31 2020-12-08 Abcentra, Llc Methods for treating systemic lupus erythematosus with an anti-apolipoprotein B antibody
US10434141B2 (en) 2016-05-31 2019-10-08 Abcentra, Llc Methods for treating systemic lupus erythematosus with an anti-apolipoprotein B antibody
CN112423783A (zh) * 2018-05-30 2021-02-26 德国癌症研究中心 组合的预防性和治疗性疫苗
KR20230042053A (ko) * 2020-07-22 2023-03-27 (주)쓰리에이치바이오 면역 치료제용 펩타이드
KR20220054225A (ko) * 2020-10-23 2022-05-02 에스케이바이오사이언스(주) 외래 항원을 코딩하는 유전물질을 포함하는, 타겟 조직의 크기 또는 부피 축소용 백신 조성물 또는 키트
WO2023204693A1 (ko) * 2022-04-22 2023-10-26 에스케이바이오사이언스 주식회사 타겟 조직의 크기 또는 부피 축소용 조성물 또는 이를 포함하는 키트

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0406316B1 (en) 1988-03-25 1995-01-18 Mallinckrodt Veterinary, Inc. Peptides derived from Foot and mouth disease virus
US5759551A (en) 1993-04-27 1998-06-02 United Biomedical, Inc. Immunogenic LHRH peptide constructs and synthetic universal immune stimulators for vaccines
US6284533B1 (en) 1996-05-01 2001-09-04 Avant Immunotherapeutics, Inc. Plasmid-based vaccine for treating atherosclerosis
US6541011B2 (en) * 1998-02-11 2003-04-01 Maxygen, Inc. Antigen library immunization
GB9812613D0 (en) * 1998-06-11 1998-08-12 Smithkline Beecham Biolog Vaccine
CZ20022971A3 (cs) * 2000-03-03 2003-02-12 Smithkline Beecham Biologicals S. A. Vakcinační prostředek vhodný pro léčbu aterosklerózy
RU2313536C2 (ru) 2000-09-04 2007-12-27 Хио-Дзоон КИМ Конкатемер пептида, индуцирующего выработку антител против аполипопротеина в-100, вакцина для лечения ожирения, способ получения конкатемера, полинуклеотид, экспрессирующий вектор
KR100472841B1 (ko) 2000-09-04 2005-03-07 (주)에스제이바이오메드 아포지단백질 비-100의 에피토프에 대한 모조 펩타이드,그들의 연쇄물 또는 변형체와 이들을 함유하는 백신 조성물
MY144532A (en) * 2001-08-20 2011-09-30 Lundbeck & Co As H Novel method for down-regulation of amyloid
US6954446B2 (en) 2002-06-25 2005-10-11 Motorola, Inc. Multiple mode RF communication device
CA2496409A1 (en) * 2002-08-30 2004-03-11 Glaxo Group Limited Immunogenic composition comprising an il-13 element and t cell epitopes, and its therapeutic use

Also Published As

Publication number Publication date
EP1756143A1 (en) 2007-02-28
JP2008500813A (ja) 2008-01-17
EP1756143A4 (en) 2010-10-06
KR100639397B1 (ko) 2006-10-26
JP4554672B2 (ja) 2010-09-29
CA2560539C (en) 2011-08-09
US20100240575A1 (en) 2010-09-23
EP1756143B1 (en) 2011-11-02
BRPI0508916A (pt) 2007-08-14
WO2005087800A1 (en) 2005-09-22
CA2560539A1 (en) 2005-09-22
AU2005222019B2 (en) 2008-01-31
KR20050093280A (ko) 2005-09-23
AU2005222019A1 (en) 2005-09-22
MXPA06010635A (es) 2007-03-26
CN1956995A (zh) 2007-05-02
ATE531730T1 (de) 2011-11-15
CN1956995B (zh) 2011-03-30
US7829667B2 (en) 2010-11-09
RU2341534C2 (ru) 2008-12-20

Similar Documents

Publication Publication Date Title
US11229694B2 (en) Vaccine against RSV
US7220545B2 (en) Peptide fragment of respiratory syncytial virus protein G, immunogenic agent, pharmaceutical composition containing it and preparation method
JP2005517380A5 (ru)
US5039522A (en) Immunogens containing peptides with an attached hydrophobic tail for adsorption to hepatitis B virus surface antigen
IL152625A (en) Synthetic but not amyloidogenic immunogenic peptides equivalent to amyloid b to elicit an immune response to amyloid b and amyloid deposits
OA10129A (en) Retro- inverso- and retro-inverso synthetic peptide analogues
CN105188745A (zh) 稳定化的可溶性融合前rsv f多肽
EA004497B1 (ru) Коровые антигенные частицы hbv с множественными иммуногенными компонентами, связанными посредством пептидных лигандов
CA2299677A1 (en) Preparation and use of recombinant influenza a virus m2 constructs and vaccines
CN112535730B (zh) 新型冠状病毒多肽疫苗及其应用
AU2004245859B2 (en) Cell surface expression vector of SARS virus antigen and microorganisms transformed thereby
AU8812398A (en) Syncytial respiratory virus epitopes and antibodies comprising them, useful in diagnosis and therapy
RU2006136786A (ru) Иммуногенные гибридные полипептиды против ожирения и вакцинная композиция против ожирения, включающая эти полипептиды
CN117304279A (zh) 一种重组rsv f蛋白及其应用
RU2009115688A (ru) Иммуногенные гибридные полипептиды против ожирения и композиция вакцин против ожирения, содержащая эти полипептиды
CA2337754A1 (en) Recombinant multivalent malarial vaccine against plasmodium falciparum
CN102464721A (zh) 针对人肠道病毒71型的重组广谱性疫苗
JP2567024B2 (ja) 熱帯熱マラリア原虫分裂小体の抗原ペプチド
Zuckerman Subunit, recombinant and synthetic hepatitis B vaccines
Cruz et al. Immunogenicity comparison of a multi‐antigenic peptide bearing V3 sequences of the human immunodeficiency virus type 1 with TAB9 protein in mice
US20240189407A1 (en) Modified virus-like particles of bacteriophage ap205
RU2021112253A (ru) Вирусоподобные частицы cmv, модифицированные путем слияния
Albrecht et al. Expression of CaMV ORF IV in Escherichia coli
CN114634579A (zh) 一种抗新冠病毒基因工程疫苗
KR890005071B1 (ko) 재조합 dna 플라스미드를 이용하여 형질전환된 이. 콜라이 세포로부터 프리-s2 코우드로 된 펩티드 및 융합 단백질 효소의 제조방법

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20130319